Nurix Therapeutics, Inc. officer Johannes van Houte filed a Form 144 notice on November 4, 2026, disclosing a proposed sale of 4,769 shares of common stock acquired through restricted stock units, with an aggregate market value of $123,135.58.

Key Highlights

  • Filer and role: Johannes van Houte, identified as an officer of Nurix Therapeutics, Inc.
  • Proposed sale: 4,769 shares of common stock, with an aggregate market value of $123,135.58, to be sold on or around November 4, 2026.
  • Source of shares: The 4,769 shares were acquired on October 30, 2026, via restricted stock units granted by the issuer.
  • Prior sales in past 3 months: Van Houte sold 2,834 shares on October 30, 2026, for gross proceeds of $74,474.97.
  • Total shares outstanding: 109,249,814 shares of common stock, according to the filing.
  • Trading plan: The filing indicates reliance on a Rule 10b5-1 plan adopted on February 3, 2026, with Morgan Stanley Smith Barney LLC Executive Financial Services named as broker.

Van Houte RSU-Derived Share Sale at Nurix Therapeutics

According to the Form 144 filed with the U.S. Securities and Exchange Commission on November 4, 2026, Johannes van Houte, an officer of Nurix Therapeutics, Inc. (NASDAQ:NRIX), provided notice of a proposed sale of 4,769 shares of Nurix common stock. The aggregate market value of the shares to be sold was listed as $123,135.58. The filing identified Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY, as the executing broker.

The filing disclosed that the 4,769 shares were acquired on October 30, 2026, through restricted stock units issued by Nurix Therapeutics, Inc. as the acquiring party. No cash consideration was involved in the acquisition, with payment listed as "N/A." The approximate date of the proposed sale was listed as November 4, 2026, and the securities are to be sold on NASDAQ.

In the section covering securities sold during the past three months, the filing reported that van Houte sold 2,834 shares of Nurix common stock on October 30, 2026, generating gross proceeds of $74,474.97. The filing also noted that the proposed sale is being made in reliance on a Rule 10b5-1 written trading plan adopted on February 3, 2026. The total shares of common stock outstanding at the time of the filing were listed as 109,249,814.

What Was Disclosed

A Form 144 notice was filed on November 4, 2026, by Nurix Therapeutics officer Johannes van Houte, covering a proposed sale of 4,769 RSU-derived common shares valued at $123,135.58, under a Rule 10b5-1 plan adopted February 3, 2026.